整合胎盘灌注实验与妊娠PBPK模型预测多拉韦林母胎暴露
研究采用离体胎盘灌注实验(n=8)结合妊娠生理药代动力学模型,预测多拉韦林在妊娠26、32、40周的母胎暴露。结果显示妊娠40周母体多拉韦林AUC0-24h较非妊娠女性降低55%,各孕期预测母体总谷浓度均低于0.23 mg/L疗效目标,胎盘透过广泛且胎儿暴露可观。建议接受多拉韦林治疗的孕妇进行治疗药物和病毒载量监测。
要点
- 妊娠40周母体多拉韦林AUC0-24h较非妊娠女性降低55%。
- 妊娠26、32、40周预测母体总谷浓度均低于0.23 mg/L疗效目标。
- 多拉韦林胎盘透过广泛,模型预测胎儿暴露可观,需临床胎儿安全性数据。
核心结论
- 妊娠期多拉韦林母体暴露显著降低,可能导致疗效受损。
- 建议接受多拉韦林治疗的孕妇进行治疗药物和病毒载量监测。
- 预测胎儿多拉韦林暴露可观,需临床胎儿安全性数据。
研究设计与样本
- 离体胎盘灌注实验采用闭合-闭合构型,母胎和胎母双向(n=8)。
- 基于灌注数据建立机制性胎盘模型,衍生内在胎盘转运参数。
- 在Simcyp中建立多拉韦林母体和胎儿全身妊娠PBPK模型,预测妊娠26、32、40周暴露。
主要发现
- 妊娠40周母体多拉韦林AUC0-24h较非妊娠女性降低55%。
- 妊娠26、32、40周预测母体总多拉韦林GM Ctrough均低于0.23 mg/L疗效目标。
- 灌注实验显示多拉韦林广泛穿过胎盘,PBPK模型预测胎儿多拉韦林暴露可观。
关键数值与推荐
- 疗效目标:多拉韦林总谷浓度0.23 mg/L,源自体内暴露-反应分析。
- 妊娠40周母体AUC0-24h降低55%。
- 预测母体总GM Ctrough在妊娠26、32、40周均低于0.23 mg/L。
临床怎么用
- 妊娠期使用多拉韦林应进行治疗药物监测和病毒载量监测。
- 关注胎儿多拉韦林暴露,积累临床胎儿安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Doravirine is currently not recommended for pregnant women living with human immunodeficiency virus because efficacy and safety data are lacking. This study aimed to predict maternal and fetal doravirine exposure by integrating human placenta perfusion experiments with pregnancy physiologically based pharmacokinetic (PBPK) modeling. METHODS: Ex vivo placenta perfusions were performed in a closed-closed configuration, in both maternal-to-fetal and fetal-to-maternal directions (n = 8). To derive intrinsic placental transfer parameters from perfusion data, we developed a mechanistic placenta model. Next, we developed a maternal and fetal full-body pregnancy PBPK model for doravirine in Simcyp, which was parameterized with the derived intrinsic placental transfer parameters to predict in vivo maternal and fetal doravirine exposure at 26, 32, and 40 weeks of pregnancy. The predicted total geometric mean (GM) trough plasma concentration (Ctrough) values were compared with the target (0.23 mg/L) derived from in vivo exposure-response analysis. RESULTS: A decrease of 55% in maternal doravirine area under the plasma concentration-time curve (AUC)0-24h was predicted in pregnant women at 40 weeks of pregnancy compared with nonpregnant women. At 26, 32, and 40 weeks of pregnancy, predicted maternal total doravirine GM Ctrough values were below the predefined efficacy target of 0.23 mg/L. Perfusion experiments showed that doravirine extensively crossed the placenta, and PBPK modeling predicted considerable fetal doravirine exposure. CONCLUSION: Substantially reduced maternal doravirine exposure was predicted during pregnancy, possibly resulting in impaired efficacy. Therapeutic drug and viral load monitoring are advised for pregnant women treated with doravirine. Considerable fetal doravirine exposure was predicted, highlighting the need for clinical fetal safety data.
引用
- Bukkems VE, van Hove H, Roelofsen D, et al. Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments. Clin Pharmacokinet. 2022. PMID: 35579825. doi:10.1007/s40262-022-01127-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。